Eli Lilly and Company

Other

Joslin Diabetes Center, Inc.

Douglas Kirk Ways

Michael R Jirousek

Lawrence E Stramm

Louis Vignati

George Liang King

Lloyd Paul Aiello

William F Heath, Jr

Richard Ernest Gilbert

Daniel Wierda

A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N, N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl)&rsqb;-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.

Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

A method for treating CMV infection and disease conditions associated therewith is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N,N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl)&rsqb;-1(H)-pyrrole-2,5-dione hydrochloride salt.

Therapeutic treatment for cytomegalovirus infection

A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N,N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N -dimethylamino)butane)-bis-(3,3&prime;-indolyl)&rsqb;-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.

Use of protein kinase C inhibitors to enhance the clinical efficacy of radiation therapy

A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N,N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl)&rsqb;-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Therapeutic treatment for VEGF related diseases

A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N, N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;-(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl)&rsqb;-,(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.

A method for treating renal dysfunctions is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N, N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl) &rsqb;-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Therapeutic treatment for renal dysfunction

A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Therapeutic treatment for VEGF related ocular diseases

A method for treating HIV infection is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis-(3,3'-indo lyl)]-1(H)-pyrrole-2,5-dione or its acid salt.

Therapeutic treatment for HIV infection

A method for treating asthma and disease conditions associated therewith is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2'-ethoxy)-3''-(O)-4''-(N,N-dimethylamino)-butane)-bi s-(3,3'-indoly1)]-1 (H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.

Therapeutic treatment for asthma

Methods for inhibiting activation and/or proliferation of T cells and B cells and for treating autoimmune diseases and/or disease manifestations are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis-(3,3'-indo ly 1)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.

Therapeutic treatment for autoimmune diseases

A method for treating sexual dysfunctions is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly1)]-1(H)-pyrrole-2,5-dione, particularly its hydrochloride, or mesylate salt.

Therapeutic treatment for sexual dysfunctions

A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the .beta.-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.

Therapeutic treatment for skin disorders

A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, (S)-3,4-�N,N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.

Therapetutic treatment for human T cell lymphotrophic virus type 1

A method for treating endothelial cell dysfunction, such as associated with cardiovascular disease are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-�N,N'-1,1'-((27'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bi s-(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.

Growing community of inventors

Indianapolis, IN, United States of America

Douglas Kirk Ways